A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone

International Journal of Dermatology

Volumn 55, Issue 5, 2016, Pages e250-e255

  Mukhopadhyay, Debanjan ^a   Mukherjee, Shibabrata ^a   Ghosh, Susmita ^a   Roy, Susmita ^a   Saha, Bibhuti ^b   Das, Nilay Kanti ^c   Chatterjee, Mitali ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; MILTEFOSINE; TESTOSTERONE; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE; PROTOZOON ANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POST KALA AZAR DERMAL LEISHMANIASIS; SEX DIFFERENCE; SKIN LEISHMANIASIS; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VISCERAL LEISHMANIASIS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; FEMALE; IMMUNOLOGY; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; NEGLECTED DISEASE; PARASITOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIBODIES, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; NEGLECTED DISEASES; PHOSPHORYLCHOLINE; SEX FACTORS; TESTOSTERONE; YOUNG ADULT;

EID: 84962715519     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.13048     Document Type: Article

References (27)

1. Klein SL. Hormonal and immunological mechanisms mediating sex differences in parasite infection. Parasite Immunol 2004; 26: 247-264.
2. Fish EN. The X-files in immunity: sex biased differences predispose immune responses. Nat Rev Immunol 2008; 8: 737-744.
3. Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol 2014; 35: 97-104.
4. Marttila S, Jylhävä J, Nevalainen T, et al. Transcriptional analysis reveals gender-specific changes in the aging of the human immune system. PLoS One 2013; 8: e66229.
5. Bernin H, Lotter H. Sex bias in the outcome of human tropical infectious diseases: influence of steroid hormones. J Infect Dis 2014; 209: S107-S113.
6. Guerra-Silveira F, Abad-Franch F. Sex bias in infectious disease epidemiology: patterns and processes. PLoS One 2013; 8: e62390.
7. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3: 87-98.
8. Ganguly S, Das NK, Barbhuiya JN, et al. Post-kala-azar dermal leishmaniasis - an overview. Int J Dermatol 2010; 49: 921-931.
9. Cecílio P, Pérez-Cabezas B, Santarém N, et al. Deception and manipulation: the arms of Leishmania, a successful parasite. Front Immunol 2014; 5: 480.
10. Lezama-Dávila CM, Isaac-Márquez AP, Barbi J, et al. 17Beta-estradiol increases Leishmania mexicana killing in macrophages from DBA/2 mice by enhancing production of nitric oxide but not pro-inflammatory cytokines. Am J Trop Med Hyg 2007; 76: 1125-1127.
11. Snider H, Lezama-Davila C, Alexander J, et al. Sex hormones and modulation of immunity against leishmaniasis. NeuroImmunoModulation 2009; 16: 106-113.
12. Musa AM, Khalil EA, Raheem MA, et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002; 96: 765-772.
13. Das VN, Ranjan A, Pandey K, et al. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India. Am J Trop Med Hyg 2012; 86: 959-961.
14. Uranw S, Ostyn B, Rijal A, et al. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010). PLoS Negl Trop Dis 2011; 5: e1433.
15. Islam S, Kenah E, Bhuiyan MA, et al. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh. Am J Trop Med Hyg 2013; 89: 345-353.
16. Ganguly S, Das NK, Panja M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis 2008; 197: 1762-1771.
17. Mukhopadhyay D, Das NK, Roy S, et al. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J Infect Dis 2011; 204: 1427-1436.
18. Mukhopadhyay D, Das NK, De Sarkar S, et al. Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2012; 106: 668-676.
19. Singh A, Ramesh V, Ramam M. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients. Indian J Dermatol Venereol Leprol 2014; 81: 29-34.
20. Das NK, Singh SK, Ghosh S, et al. Case series of misdiagnosis with rK39 strip test in Indian leishmaniasis. Am J Trop Med Hyg 2011; 84: 688-691.
21. Singh RP, Picado A, Alam S, et al. Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India. Trop Med Int Health 2012; 17: 1345-1348.
22. Murback ND, Hans Filho G, Nascimento RA, et al. American cutaneous leishmaniasis: clinical, epidemiological and laboratory studies conducted at a university teaching hospital in Campo Grande, Mato Grosso do Sul, Brazil. An Bras Dermatol 2011; 86: 55-63.
23. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol 2011; 38: 419-431.
24. Travi BL, Osorio Y, Melby PC, et al. Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. Infect Immun 2002; 70: 2288-2296.
25. Matlashewski G, Arana B, Kroeger A, et al. Research priorities for elimination of visceral leishmaniasis. Lancet Glob Health 2014; 2: e683-e684.
26. Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?. Bull World Health Organ 1992; 70: 341-346.
27. Mukhopadhyay D, Saha P, Chatterjee M. Targets for immunochemotherapy in leishmaniasis. Expert Rev Anti Infect Ther 2012; 10: 261-264.